StemCells Inc. (STEM) Provides Update On Its Phase 1/2 Study In Spinal Cord Injury
5/19/2014 9:28:09 AM
NEWARK, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in two patients have now been observed in two additional patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by